Stocks of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) traded higher last session on Wall Street, down -1.17% to $121.18.
JAZZ stock price is now -0.91% away from the 50-day moving average and 7.29% away from the 200-day moving average. The market capitalization of the company currently stands at $7.33B.
With the price target enhanced from $140 to $175, Morgan Stanley Upgraded its rating from Equal-Weight to Overweight for Jazz Pharmaceuticals plc (NASDAQ: JAZZ). On June 05, 2024, Goldman recently initiated its ‘Buy’ rating on the stock quoting a target price of $169, while ‘Robert W. Baird’ rates the stock as ‘Outperform’
In other news, COZADD BRUCE C, Chairman & CEO sold 1,500 shares of the company’s stock on Jan 02 ’25. The stock was sold for $185,145 at an average price of $123.43. Upon completion of the transaction, the Chairman & CEO now directly owns 425,525 shares in the company, valued at $51.57 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 02 ’25, Officer COZADD BRUCE C bought 1,500 shares of the business’s stock. A total of $185,145 was incurred on buying the stock at an average price of $123.43. A total of 4.21% of the company’s stock is owned by insiders.
During the past 12 months, Jazz Pharmaceuticals plc has had a low of $99.06 and a high of $134.17. As of last week, the company has a debt-to-equity ratio of 1.49, a current ratio of 4.26, and a quick ratio of 3.74. According to the stock market information, the enterprise value for the company is $10912163840, which is based on a 17.45 price-to-earnings ratio, a 1.10 price-to-earnings-growth ratio, and a beta of 0.56. The fifty day moving average price for JAZZ is $122.2968 and a two-hundred day moving average price translates $112.94895 for the stock.
The latest earnings results from Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was released for 2024-09-30. The net profit margin was 11.60% and return on equity was 12.09% for JAZZ. The company reported revenue of $1.05 billion for the quarter, compared to $972.14 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 8.52 percent.
